doravirine lamuvidine tenofovir disoproxil fumarate (TBC)

Original post, click here

Generic Name: doravirine lamuvidine tenofovir disoproxil fumarate

Brand Name: TBC

Manufacturer: Merck Canada Inc.

Indications: HIV-1

Manufacturer Requested Reimbursement Criteria1:

​For the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine, lamivudine, or tenofovir.

Submission Type: New Combination

Project Status: Pending

Call For Patient Input: September 14, 2018

Patient Input Closed: November 5, 2018

Anticipated Date: October 15, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback